 "Never certified any traditional medicine as a cure for Covid-19: WHO")
Putting all controversies to rest, the World Health Organization (WHO) on Friday said that it never certified any traditional medicine as a cure for Covid-19. WHO's clarification came via a tweet that is believed to have been motivated by the controversy that arose after Patanjali Ayurved relaunched a medicine on the same day. In its tweet, the health advisory organisation wrote: “WHO has not reviewed or certified the effectiveness of any traditional medicine for the treatment of #Covid.”
Earlier in the day, the firm had relaunched its Coronil medicine, which it claims can cure Covid-19 and provide adequate immunity against.
In the presence of the country’s Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari, Patanjali MD Acharya Balkrishna said that Coronil has been granted a certificate of pharmaceutical product, licensed by the Drugs Controller General of India, in accordance with the WHO's Good Manufacturing Practices.
Earlier in the day, the firm had relaunched its Coronil medicine, which it claims can cure Covid-19 and provide adequate immunity against.
In the presence of the country’s Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari, Patanjali MD Acharya Balkrishna said that Coronil has been granted a certificate of pharmaceutical product, licensed by the Drugs Controller General of India, in accordance with the WHO's Good Manufacturing Practices.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%